November 13th 2023
New study findings conflict with long-understood associations between maternal depression and the postpartum period and highlight the potential need for public health policy revisions.
Oral Chemotherapy Parity Legislation: Opportunities for Cancer Care Equity
1.0 Credit / Law, Oncology
View More
Therapeutic Strategies for Bipolar Disorder: Recognizing the Intricacies in Disease Management and Considerations for Pharmacists Across Practice Settings
2.0 Credits / Neurology, Psychiatry
View More
Preventing and Managing Controlled Substance Diversion Across Health Care Settings
2.0 Credits / Law
View More
Treatment Advancements and Management Strategies in Bipolar Disorder to Mitigate Challenges to Patient Care
1.0 Credit / Neurology, Psychiatry
View More
Risks and Liabilities in Pharmacy Practice
1.0 Credit / Law
View More
The Value of Early Intervention With Long-Acting Injectable Antipsychotics to Improve Adherence and Treatment of Schizophrenia
1.5 Credits / Neurology, Psychiatry
View More
Managing Bipolar Disorder: The Pharmacist’s Role in Delivering Quality Care
1.0 Credits / Psychiatry
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Mind-Body Resilience for Women: A Focus on Depression
Developing innovative solutions for women with depression, accounting for differences in gender and sex, are critically important
NDA for Zuranolone for Depression Accepted by FDA
February 7th 2023Zuranolone, a fast-acting neuroactive steroid that can take effect in 14 days, has been assigned a PDUFA action date of Aug. 5, 2023 by the FDA. It can be used to treat patients with major depressive disorder and postpartum depression.
Cardiovascular Disease Risk Not Significantly Increased ADHD Medications
January 17th 2023A recent study found that the risk of cardiovascular diseases was not significantly greater in patients taking medications for attention-deficit/hyperactivity disorder (ADHD), but investigators were not able to rule out a mild risk increase.
Coumadin No Worse for Mental Function Than Pradaxa, When Well Administered
December 20th 2022Pradaxa (dabigatran) and Coumadin (warfarin) came out even in this randomized study. The Brazilian researchers who conducted the study said one explanation for the result is that use of Coumadin was exceptionally well managed because the patients were enrolled a study.